In-Licensing

CancerGuide is actively in-licensing and commercializing high-value, novel technology to assist clinicians with their mission to improve the management of patients diagnosed with cancer.  

Aided by its comprehensive development and commercialization agreement with Laboratory Corporation of America® Holdings (LabCorp®), CancerGuide provides an innovative development-to-commercial market platform for emerging molecular oncology diagnostic technologies, including access to early adopting oncologists and pathologists.   

We have the capabilities to take promising diagnostic technologies, through analytical validation, to clinical validation, to a commercially available assay, compliant with the applicable regulatory bodies. This includes the "locking-down" of the clinical product intended use, designing and implementing a definitive pathway to establish ”clinical utility", and commercial management of regulatory, clinical validation, reimbursement, and research & development efforts.

CancerGuide is not locked into any specific technology or platform, but is focused on developing solutions that will facilitate broad access to the promising technology. 

CancerGuide would like to be your high-value oncology diagnostic commercialization partner.  If your company or institution is actively licensing novel technology in the oncology field, please register by clicking In-Licensing Registration, with a brief description of your diagnostic technology, platform, intended use, and a listing of peer-reviewed publications.  We look forward to hearing from you.